ecrin-mdr-crcClinical2014AdenocarcinomaEndometrial CancerLung cancerColorectal cancerFallopian Tube CancerBreast cancerEndometrial NeoplasmsBladder cancerEsophagus cancerOvarian CancerSmall cell lung cancerHead and Neck cancerFallopian Tube NeoplasmsPancreatic cancerNon-small cell lung cancerAdvanced solid tumorsCarcinoma, Ovarian EpithelialOvarian NeoplasmsGastric cancerProstate cancerSolid TumorsAdenocarcinomaEndometrial CancerLung CancerSmall Cell Lung CancerAdvanced Solid TumorsFallopian Tube CancerColorectal CancerBladder CancerPancreatic CancerEndometrial NeoplasmsBreast CancerOvarian CancerEsophagus CancerFallopian Tube NeoplasmsNon-small Cell Lung CancerCarcinoma, Ovarian EpithelialGastric CancerProstate CancerHead And Neck CancerOvarian NeoplasmsSolid TumorsInterventionalhttps://newmdr.ecrin.org/Study/2176096United States10Liposomal doxorubicinLiver cancerSerous tumorGranulosa tumorClear Cell tumorKidney cancerHepatobiliary cancerDoxorubicinSkin cancerECRIN MDRCompletedfalseEffects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid TumorsThis is a Phase I study to test the safety, pharmacokinetics and effectiveness of STM 434 alone, or in combination with liposomal doxorubicin, in patients with ovarian cancer or other advanced solid tumors.2014-10-152176096NCT02262455